The maker of a popular medicine for schizophrenia has notified doctors that it minimized potentially fatal safety risks and made misleading claims about the drug in promotional materials.
Janssen Pharmaceutic Products sent a two-page letter to the health care community this past week to clarify the risks of Risperdal, Carol Goodrich, a spokeswoman for the Johnson & Johnson subsidiary, said Saturday.
You can skip to the end and leave a response. Pinging is currently not allowed.
Join the Conversation! Post a Comment:
Last reviewed: By John M. Grohol, Psy.D. on 27 Jul 2004






